Litcius/Paper detail

Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials

Amanda Leach, Nicole Wilson, Beth Arrowsmith, Jemima Beissbarth, Edward Kim Mulholland, Mathuram Santosham, Paul J. Torzillo, Peter McIntyre, Heidi Smith‐Vaughan, Mark D. Chatfield, Deborah Lehmann, Michael Binks, Anne B. Chang, Jonathan R. Carapetis, Vicki Krause, Ross Andrews, Tom Snelling, Sue Skull, Paul V. Licciardi, Victor M. Oguoma, Peter S Morris

2022The Lancet Infectious Diseases13 citationsDOI

Topics & Concepts

MedicinePneumococcal conjugate vaccineOtitisBooster dosePediatricsHaemophilus influenzaeCarriageImmunogenicityRandomized controlled trialConjugate vaccineBooster (rocketry)Internal medicineStreptococcus pneumoniaeImmunologyImmunizationSurgeryAntibodyBiologyAstronomyPathologyGeneticsBacteriaPhysicsPneumonia and Respiratory InfectionsBacterial Infections and VaccinesRespiratory viral infections research
Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials | Litcius